Request for Information: HIV National Strategic Plan 2021-2025 Available for Public Comment, 77472-77473 [2020-26586]

Download as PDF 77472 Federal Register / Vol. 85, No. 232 / Wednesday, December 2, 2020 / Notices TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1 Activity; 21 CFR section Number of respondents Number of disclosures per respondent Total annual disclosures Average burden per disclosure Total hours Nutrient labeling; §§ 107.10(a) and 107.20 ......................... 5 13 65 8 520 1 There are no capital costs or operating and maintenance costs associated with the information collection. the past decade—and people with HIV in care and treatment are living longer, healthier lives. In 2018 the estimated number of new HIV infections was 36,400. A robust prevention toolbox that Dated: November 23, 2020. includes pre-exposure prophylaxis Lauren K. Roth, (PrEP), post-exposure prophylaxis Acting Principal Associate Commissioner for (PEP), and syringe services programs Policy. (SSPs) has lowered a person’s risk of [FR Doc. 2020–26537 Filed 12–1–20; 8:45 am] acquiring HIV. Research in recent years BILLING CODE 4164–01–P has proven that people with HIV who take antiretroviral therapy achieve and maintain an undetectable viral load, not DEPARTMENT OF HEALTH AND protect their health but also have HUMAN SERVICES effectively no risk of transmitting HIV through sex. Request for Information: HIV National This stability in the annual number of Strategic Plan 2021–2025 Available for new infections, though, has further Public Comment illuminated opportunities for focused efforts. According to the most recent AGENCY: Office of the Secretary, available data, less than one-half Department of Health and Human (38.9%) of the U.S. population have Services. ever been tested for HIV 1 and an ACTION: Notice. estimated 161,800 (14%) people with SUMMARY: The Department of Health and HIV are unaware of their status.2 Only 63% of people diagnosed with HIV are Human Services’ (HHS) Office of Infectious Disease and HIV/AIDS Policy virally suppressed.3 Approximately 80% of new HIV infections are due to (OIDP) in the Office of the Assistant Secretary for Health (OASH) announces people who do not know they have HIV or are not receiving regular care,4 and the draft HIV National Strategic Plan: A only 18% of the approximately 1.2 Roadmap to End the HIV Epidemic million people indicated for PrEP are (2021–2025) (HIV Plan) available for receiving it.5 6 public comment. The draft HIV Plan may be reviewed at www.hiv.gov. 1 National HIV Testing Day—June 27, 2019. DATES: All comments must be received MMWR. 2019;68:561. doi: https://dx.doi.org/ by 5:00 p.m. ET on December 14, 2020 10.15585/mmwr.mm6825a1. 2 Centers for Disease Control and Prevention. to be considered. Estimated HIV incidence and prevalence in the ADDRESSES: All comments must be United States, 2014–2018. HIV Surveillance submitted electronically to Supplemental Report 2020;25(1). Accessed HIVPlanComments@hhs.gov to be September 28, 2020. https://www.cdc.gov/hiv/ library/reports/hiv-surveillance.html. considered. We estimate compliance with our infant formula labeling requirements in §§ 107.10(a) and 107.20 requires 520 hours annually. FOR FURTHER INFORMATION CONTACT: Harold J. Phillips, OIDP, Harold.Phillips@hhs.gov, 202–725– 8872. The National HIV/AIDS Strategy, first released in 2010 and updated in 2015, changed the way that Americans talk about HIV and the ways that stakeholders prioritize and coordinate resources and deliver prevention and care services that support people with HIV or at risk for HIV. As a result, the nation’s new HIV infections have declined from their peak in the mid1980s—although remaining stable over SUPPLEMENTARY INFORMATION: VerDate Sep<11>2014 17:39 Dec 01, 2020 Jkt 253001 3 Harris NS, Johnson AS, Huang YLA, et al. Vital Signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis—United States, 2013–2018. MMWR. 2019;68:1117–1123. doi: https://dx.doi.org/ 10.15585/mmwr.mm6848e1. 4 Li Z, Purcell DW, Sansom SL, et al. Vital Signs: HIV transmission along the continuum of care— United States, 2016. MMWR. 2019;68:267–272. Figure 1. doi: https://dx.doi.org/10.15585/ mmwr.mm6811e1. 5 Harris NS, Johnson AS, Huang YLA, et al. Vital Signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis—United States, 2013–2018. MMWR. 2019;68:1117–1123. doi: https://dx.doi.org/ 10.15585/mmwr.mm6848e1. 6 Centers for Disease Control and Prevention. HIV Surveillance Data Tables (early release): Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): HIV PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 To respond and address the HIV public health epidemic, OASH through OIDP, in collaboration with a steering committee composed of a wide array of federal partners, has led and coordinated development of the HIV Plan. Opportunities for public input were provided, and public comments received were reviewed and analyzed, to help inform development of the components of the HIV Plan. The HIV Plan covers the entire country, provides a roadmap across the federal government, non-federal partners and stakeholders in all sectors of society, and encourages integration of several key components that are vital to our collective work. The HIV Plan is the nation’s third consecutive national HIV strategy. It sets forth bold targets for ending the HIV epidemic in the United States by 2030, including a 75% reduction in new HIV infections by 2025 and a 90% reduction by 2030. The HIV Plan articulates goals, objectives, and strategies to prevent new infections, treat people with HIV to improve health outcomes, reduce HIVrelated disparities, and better integrate and coordinate the efforts of all partners to end the HIV epidemic in the United States. The HIV Plan also establishes indicators to measure progress, with quantitative targets for each indicator, and designates populations disproportionately impacted by and at risk for HIV as well as key areas of focus. The order of goals, objectives, and strategies does not indicate any prioritization, and many are intertwined. The following are the HIV Plan’s vision and four goals: Vision: The United States will be a place where new HIV infections are prevented, every person knows their status, and every person with HIV has high-quality care and treatment and lives free from stigma and discrimination. This vision includes all people, regardless of age, sex, gender identity, sexual orientation, race, diagnoses and linkage to HIV medical care, 2019 (reported through December 2019); and preexposure prophylaxis (PrEP)—2018, updated. HIV Surveillance Data Tables 2020;1(2). Accessed October 16, 2020. https://www.cdc.gov/hiv/library/ reports/surveillance-data-tables/. E:\FR\FM\02DEN1.SGM 02DEN1 Federal Register / Vol. 85, No. 232 / Wednesday, December 2, 2020 / Notices ethnicity, religion, disability, geographic location, or socioeconomic circumstance. Goals 1. Prevent new HIV infections; 2. Increase knoweldge of HIV status; 3. Reduce HIV-related disparities and health inequities; and 4. Achieve integrated, coordinated efforts that adddress the HIV epidemic among all partners and stakeholders. Information Needs The draft HIV Plan may be reviewed at: www.hiv.gov. OIDP seeks to obtain feedback from external stakeholders on the following: 1. Do the draft plan’s goals, objectives, and strategies appropriately address the HIV epidemic? 2. Are there any critical gaps in the HIV Plan’s goals, objectives, and strategies? If so, please specify the gaps. 3. Do any of the HIV Plan’s goals, objectives and strategies cause concern? If so, please specify the goal, objective or strategy, and describe the concern regarding it. Each commenter is limited to a maximum of seven pages. Authority: 77 FR 15761 (March 16, 2012). Dated: November 25, 2020. B. Kaye Hayes, Acting Director, Office of Infectious Disease and HIV/AIDS Policy. [FR Doc. 2020–26586 Filed 12–1–20; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Alcohol Abuse and Alcoholism Initial Review Group Neuroscience Review Subcommittee. 17:39 Dec 01, 2020 Jkt 253001 Dated: November 25, 2020. Patricia B. Hansberger, Supervisory Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–26561 Filed 12–1–20; 8:45 am] BILLING CODE 4140–01–P INTERNATIONAL TRADE COMMISSION [Investigation Nos. 701–TA–631 and 731– TA–1463–1464 (Final)] Forged Steel Fittings From India and Korea BILLING CODE 4150–43–P VerDate Sep<11>2014 Date: March 3, 2021. Time: 8:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Health, National Institute on Alcohol Abuse and Alcoholism, 6700 B Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Beata Buzas, Ph.D., Scientific Review Officer, Extramural Project Review Branch, Office of Extramural Activities, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Room 2116, MSC 6902, Bethesda, MD 20892, 301–443–0800, bbuzas@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; 93.701, ARRA Related Biomedical Research and Research Support Awards., National Institutes of Health, HHS) Determinations On the basis of the record 1 developed in the subject investigations, the United States International Trade Commission (‘‘Commission’’) determines, pursuant to the Tariff Act of 1930 (‘‘the Act’’), that an industry in the United States is materially injured by reason of imports of forged steel fittings from India and Korea, provided for in subheadings 7307.92.30, 7307.92.90, 7307.93.30, 7307.93.60, 7307.93.90, 7307.99.10, 7307.99.30, and 7307.99.50 of the Harmonized Tariff Schedule of the United States, that have been found by the U.S. Department of Commerce (‘‘Commerce’’) to be sold in the United States at less than fair value (‘‘LTFV’’), and to be subsidized by the government of India.2 with the Commission and Commerce by Bonney Forge Corporation (‘‘Bonney’’), Mount Union, Pennsylvania, and the United Steel, Paper and Forestry, Rubber, Manufacturing, Energy, Allied Industrial and Service Workers International Union (‘‘USW’’), Pittsburgh, Pennsylvania. The final phase of the investigations was scheduled by the Commission following notification of preliminary determinations by Commerce that imports of forged steel fittings from India were subsidized within the meaning of section 703(b) of the Act (19 U.S.C. 1671b(b)) and sold at LTFV within the meaning of 733(b) of the Act (19 U.S.C. 1673b(b)). Notice of the scheduling of the final phase of the Commission’s investigations and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register on June 19, 2020 (85 FR 37109). In light of the restrictions on access to the Commission building due to the COVID–19 pandemic, the Commission conducted its hearing through written testimony and video conference on October 15, 2020. All persons who requested the opportunity were permitted to participate. The Commission made these determinations pursuant to §§ 705(b) and 735(b) of the Act (19 U.S.C. 1671d(b) and 19 U.S.C. 1673d(b)). It completed and filed its determinations in these investigations on November 25, 2020. The views of the Commission are contained in USITC Publication 5137 (November 2020), entitled Forged Steel Fittings from India and Korea: Investigation Nos. 701–TA–631 and 731–TA–1463–1464 (Final). By order of the Commission. Issued: November 25, 2020. Jessica Mullan, Attorney Advisor. [FR Doc. 2020–26579 Filed 12–1–20; 8:45 am] BILLING CODE 7020–02–P Background The Commission instituted these investigations effective October 23, 2019, following receipt of petitions filed 1 The record is defined in § 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)). 2 Vice Chair Randolph J. Stayin not participating. PO 00000 Frm 00049 Fmt 4703 Sfmt 9990 77473 E:\FR\FM\02DEN1.SGM 02DEN1

Agencies

[Federal Register Volume 85, Number 232 (Wednesday, December 2, 2020)]
[Notices]
[Pages 77472-77473]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26586]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Request for Information: HIV National Strategic Plan 2021-2025 
Available for Public Comment

AGENCY: Office of the Secretary, Department of Health and Human 
Services.

ACTION: Notice.

-----------------------------------------------------------------------

Summary:  The Department of Health and Human Services' (HHS) Office of 
Infectious Disease and HIV/AIDS Policy (OIDP) in the Office of the 
Assistant Secretary for Health (OASH) announces the draft HIV National 
Strategic Plan: A Roadmap to End the HIV Epidemic (2021-2025) (HIV 
Plan) available for public comment. The draft HIV Plan may be reviewed 
at www.hiv.gov.

DATES: All comments must be received by 5:00 p.m. ET on December 14, 
2020 to be considered.

ADDRESSES: All comments must be submitted electronically to 
[email protected] to be considered.

FOR FURTHER INFORMATION CONTACT: Harold J. Phillips, OIDP, 
[email protected], 202-725-8872.

SUPPLEMENTARY INFORMATION: The National HIV/AIDS Strategy, first 
released in 2010 and updated in 2015, changed the way that Americans 
talk about HIV and the ways that stakeholders prioritize and coordinate 
resources and deliver prevention and care services that support people 
with HIV or at risk for HIV. As a result, the nation's new HIV 
infections have declined from their peak in the mid-1980s--although 
remaining stable over the past decade--and people with HIV in care and 
treatment are living longer, healthier lives. In 2018 the estimated 
number of new HIV infections was 36,400. A robust prevention toolbox 
that includes pre-exposure prophylaxis (PrEP), post-exposure 
prophylaxis (PEP), and syringe services programs (SSPs) has lowered a 
person's risk of acquiring HIV. Research in recent years has proven 
that people with HIV who take antiretroviral therapy achieve and 
maintain an undetectable viral load, not protect their health but also 
have effectively no risk of transmitting HIV through sex.
    This stability in the annual number of new infections, though, has 
further illuminated opportunities for focused efforts. According to the 
most recent available data, less than one-half (38.9%) of the U.S. 
population have ever been tested for HIV \1\ and an estimated 161,800 
(14%) people with HIV are unaware of their status.\2\ Only 63% of 
people diagnosed with HIV are virally suppressed.\3\ Approximately 80% 
of new HIV infections are due to people who do not know they have HIV 
or are not receiving regular care,\4\ and only 18% of the approximately 
1.2 million people indicated for PrEP are receiving it.\5\ \6\
---------------------------------------------------------------------------

    \1\ National HIV Testing Day--June 27, 2019. MMWR. 2019;68:561. 
doi: https://dx.doi.org/10.15585/mmwr.mm6825a1.
    \2\ Centers for Disease Control and Prevention. Estimated HIV 
incidence and prevalence in the United States, 2014-2018. HIV 
Surveillance Supplemental Report 2020;25(1). Accessed September 28, 
2020. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
    \3\ Harris NS, Johnson AS, Huang YLA, et al. Vital Signs: status 
of human immunodeficiency virus testing, viral suppression, and HIV 
preexposure prophylaxis--United States, 2013-2018. MMWR. 
2019;68:1117-1123. doi: https://dx.doi.org/10.15585/mmwr.mm6848e1.
    \4\ Li Z, Purcell DW, Sansom SL, et al. Vital Signs: HIV 
transmission along the continuum of care--United States, 2016. MMWR. 
2019;68:267-272. Figure 1. doi: https://dx.doi.org/10.15585/mmwr.mm6811e1.
    \5\ Harris NS, Johnson AS, Huang YLA, et al. Vital Signs: status 
of human immunodeficiency virus testing, viral suppression, and HIV 
preexposure prophylaxis--United States, 2013-2018. MMWR. 
2019;68:1117-1123. doi: https://dx.doi.org/10.15585/mmwr.mm6848e1.
    \6\ Centers for Disease Control and Prevention. HIV Surveillance 
Data Tables (early release): Core indicators for monitoring the 
Ending the HIV Epidemic initiative (preliminary data): HIV diagnoses 
and linkage to HIV medical care, 2019 (reported through December 
2019); and preexposure prophylaxis (PrEP)--2018, updated. HIV 
Surveillance Data Tables 2020;1(2). Accessed October 16, 2020. 
https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/.
---------------------------------------------------------------------------

    To respond and address the HIV public health epidemic, OASH through 
OIDP, in collaboration with a steering committee composed of a wide 
array of federal partners, has led and coordinated development of the 
HIV Plan. Opportunities for public input were provided, and public 
comments received were reviewed and analyzed, to help inform 
development of the components of the HIV Plan. The HIV Plan covers the 
entire country, provides a roadmap across the federal government, non-
federal partners and stakeholders in all sectors of society, and 
encourages integration of several key components that are vital to our 
collective work.
    The HIV Plan is the nation's third consecutive national HIV 
strategy. It sets forth bold targets for ending the HIV epidemic in the 
United States by 2030, including a 75% reduction in new HIV infections 
by 2025 and a 90% reduction by 2030. The HIV Plan articulates goals, 
objectives, and strategies to prevent new infections, treat people with 
HIV to improve health outcomes, reduce HIV-related disparities, and 
better integrate and coordinate the efforts of all partners to end the 
HIV epidemic in the United States. The HIV Plan also establishes 
indicators to measure progress, with quantitative targets for each 
indicator, and designates populations disproportionately impacted by 
and at risk for HIV as well as key areas of focus.
    The order of goals, objectives, and strategies does not indicate 
any prioritization, and many are intertwined. The following are the HIV 
Plan's vision and four goals:
    Vision: The United States will be a place where new HIV infections 
are prevented, every person knows their status, and every person with 
HIV has high-quality care and treatment and lives free from stigma and 
discrimination. This vision includes all people, regardless of age, 
sex, gender identity, sexual orientation, race,

[[Page 77473]]

ethnicity, religion, disability, geographic location, or socioeconomic 
circumstance.

Goals

    1. Prevent new HIV infections;
    2. Increase knoweldge of HIV status;
    3. Reduce HIV-related disparities and health inequities; and
    4. Achieve integrated, coordinated efforts that adddress the HIV 
epidemic among all partners and stakeholders.

Information Needs

    The draft HIV Plan may be reviewed at: www.hiv.gov.
    OIDP seeks to obtain feedback from external stakeholders on the 
following:
    1. Do the draft plan's goals, objectives, and strategies 
appropriately address the HIV epidemic?
    2. Are there any critical gaps in the HIV Plan's goals, objectives, 
and strategies? If so, please specify the gaps.
    3. Do any of the HIV Plan's goals, objectives and strategies cause 
concern? If so, please specify the goal, objective or strategy, and 
describe the concern regarding it.
    Each commenter is limited to a maximum of seven pages.

    Authority: 77 FR 15761 (March 16, 2012).

    Dated: November 25, 2020.
B. Kaye Hayes,
Acting Director, Office of Infectious Disease and HIV/AIDS Policy.
[FR Doc. 2020-26586 Filed 12-1-20; 8:45 am]
BILLING CODE 4150-43-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.